Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: A 6-month interim analysis of the 2-year, observational, prospective ACTION study

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Nüßlein, Hubert G ^a   Alten, Rieke ^b   Galeazzi, Mauro ^c   Lorenz, Hanns Martin ^d   Boumpas, Dimitrios ^e   Nurmohamed, Michael T ^f   Bensen, William G ^g   Burmester, Gerd R ^b   Peter, Hans Hartmut ^h   Rainer, Franz ⁱ   Pavelka, Karel ^j   Chartier, Melanie ^k   Poncet, Coralie ^l   Rauch, Christiane ^m   Bars, Manuela Le ^m  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY OF CRETE   (Greece)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ST JOSEPH S HOSPITAL   (Canada)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^j CHARLES UNIVERSITY   (Czech Republic)

^k Chiltern International   (France)

^l DOCS International   (France)

^m BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Abatacept; Biological agents; Effectiveness; Registries; Rheumatoid arthritis; Safety

Indexed keywords

ABATACEPT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BRONCHITIS; CANADA; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EUROPE; EUROPEAN LEAGUE AGAINST RHEUMATISM RESPONSE CRITERIA; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEART DISEASE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHYSICAL CAPACITY; PNEUMOCYSTIS PNEUMONIA; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEPSIS; TRANSIENT ISCHEMIC ATTACK; TUBERCULOSIS;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; DISABILITY EVALUATION; DRUG SUBSTITUTION; EUROPE; FEMALE; HUMANS; IMMUNOCONJUGATES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892402611     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-14     Document Type: Article

References (34)

1. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. van Vollenhoven RF, Ann Rheum Dis 2007 66 849 851 10.1136/ard.2007.069872 17576784 (Pubitemid 46999781)
2. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Arthritis Rheum 2009 61 560 568 10.1002/art.24463 19405000
3. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, Arthritis Rheum 2007 56 13 20 10.1002/art.22331 17195186 (Pubitemid 46106174)
4. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B, Arthritis Rheum 2006 54 711 715 10.1002/art.21671 16508927
5. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, Dougados M, J Rheumatol 2006 33 2433 2438 17014004
6. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Du Pan SM, Scherer A, Gabay C, Finckh A, Ann Rheum Dis 2012 71 997 999 10.1136/annrheumdis-2011-200882 22294628
7. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, Sarzi-Puttini P, Atzeni F, Montecucco C, Autoimmun Rev 2009 8 274 280 10.1016/j.autrev.2008.11.003 19017546
8. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL, Ann Rheum Dis 2007 66 1473 1478 10.1136/ard.2007.072447 17426065 (Pubitemid 350032655)
9. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Emery P, Rheumatology (Oxford) 2012 51 Suppl 5 v30 10.1093/rheumatology/kes115 22718923
10. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R, Ann Intern Med 2006 144 865 876 10.7326/0003-4819-144-12- 200606200-00003 16785475 (Pubitemid 46768126)
11. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechiński J, Li T, Teng J, Becker JC, Westhovens R, Arthritis Rheum 2008 58 953 963 10.1002/art.23397 18383390 (Pubitemid 351563996)
12. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naïve patients with RA [abstract]. Westhovens R, Kremer J, Emery P, Russell A, Li T, Aranda R, Becker JC, Zhao C, Dougados M, Ann Rheum Dis 2009 68 3 577 SAT0108
13. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M, N Engl J Med 2005 353 1114 1123 10.1056/NEJMoa050524 16162882 (Pubitemid 41317434)
14. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M, Ann Rheum Dis 2008 67 547 554 17921185 (Pubitemid 351498439)
15. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Mariette X, Gottenberg JE, Ravaud P, Combe B, Rheumatology (Oxford) 2011 50 222 229 10.1093/rheumatology/keq368 21148156
16. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML, Ann Rheum Dis 2011 70 1216 1222 10.1136/ard.2010.140129 21551512
17. Gender and previous treatment influence outcomes from abatacept in a 5-year rheumatoid arthritis cohort [Abstract]. Lindblad S, Stawiarz L, Swedish Rheumatology Quality Register, Ann Rheum Dis 2012 71 3 383 FRI0205
18. Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Schiff M, Poncet C, Bars ML, Int J Clin Rheumatol 2010 5 581 591 10.2217/ijr.10.52
19. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 (Pubitemid 18091653)
20. International Conference on Harmonisation, Good Clinical Practice: Consolidated Guideline; Notice of Availability, 62 Federal Register 90 1997 25691 25709
21. Olsen J, Good Epidemiological Practice (GEP): IEA Guidelines For Proper Conduct In Epidemiologic Research IEA-European Federation, Stewart S, Pearce P, Florey C, Du V, 2007
22. Early response to abatacept plus MTX in MTX-IR RA patients using power doppler ultrasonography: an open-label study-poster tours. D'Agostino M, Wakefield R, Berner Hammer H, Vittecoq O, Galeazzi M, Balint P, Fillipucci E, Moller I, Iagnocco A, Naredo E, Ostergaard M, Gaillez C, Kerselaers W, Van Holder K, Le Bars M, Ann Rheum Dis 2012 71 3 186 THU0095 21930734
23. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, Arthritis Rheum 1995 38 44 48 10.1002/art.1780380107 7818570
24. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL, Ann Rheum Dis 2009 68 954 960 10.1136/ard.2007.084459 18490431
25. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Aletaha D, Smolen J, Clin Exp Rheumatol 2005 23 5 Suppl 39 100 S108 16273793
26. Disease activity measures for rheumatoid arthritis. Dougados M, Aletaha D, van Riel P, Clin Exp Rheumatol 2007 25 5 Suppl 46 22 S29 17977485
27. The disease activity score and the EULAR response criteria. Fransen J, van Riel PL, Clin Exp Rheumatol 2005 23 5 Suppl 39 93 S99 16273792
28. Measurement of patient outcome in arthritis. Fries JF, Spitz P, Kraines RG, Holman HR, Arthritis Rheum 1980 23 137 145 10.1002/art.1780230202 7362664 (Pubitemid 10164318)
29. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA, J Rheumatol 1993 20 557 560 8478873 (Pubitemid 23102493)
30. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr, Arthritis Rheum 2000 43 1478 1487 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0. CO;2-M 10902749 (Pubitemid 30452465)
31. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Redelmeier DA, Lorig K, Arch Intern Med 1993 153 1337 1342 10.1001/archinte.1993.00410110045008 8507124 (Pubitemid 23169927)
32. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC, Ann Rheum Dis 2009 68 1708 1714 10.1136/ard.2008.099218 19074911
33. Prospective follow-Up of RA patients (1200 patient/years) treated with abatacept in real life: results from the ORA registry [abstract]. Gottenberg JE, Ravaud P, Bardin T, Cantagrel A, Combe B, Dougados M, et al. Ann Rheum Dis 2011 70 3 466 FRI0364
34. Forget personalised medicine and focus on abating disease activity. Smolen JS, Aletaha D, Ann Rheum Dis 2013 72 3 6 10.1136/annrheumdis-2012-202361 23136241